Ellevest Inc. Purchases Shares of 497 Axon Enterprise, Inc. (NASDAQ:AXON)

Ellevest Inc. bought a new stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 497 shares of the biotechnology company's stock, valued at approximately $295,000.

Several other large investors have also recently bought and sold shares of AXON. Friedenthal Financial raised its position in Axon Enterprise by 961.7% during the fourth quarter. Friedenthal Financial now owns 1,359 shares of the biotechnology company's stock valued at $808,000 after acquiring an additional 1,231 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Axon Enterprise by 33.1% during the third quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company's stock worth $54,466,000 after buying an additional 33,869 shares in the last quarter. Artemis Investment Management LLP boosted its stake in Axon Enterprise by 21.4% during the fourth quarter. Artemis Investment Management LLP now owns 95,113 shares of the biotechnology company's stock worth $56,528,000 after buying an additional 16,792 shares in the last quarter. Decker Retirement Planning Inc. acquired a new stake in Axon Enterprise during the fourth quarter worth $2,985,000. Finally, MRA Advisory Group lifted its holdings in shares of Axon Enterprise by 64.4% during the fourth quarter. MRA Advisory Group now owns 3,205 shares of the biotechnology company's stock valued at $1,905,000 after acquiring an additional 1,255 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.

Axon Enterprise Trading Up 0.5%

Shares of Axon Enterprise stock traded up $3.76 during midday trading on Wednesday, reaching $728.53. The company had a trading volume of 566,004 shares, compared to its average volume of 764,892. The firm has a market cap of $56.72 billion, a PE ratio of 188.25, a P/E/G ratio of 5.17 and a beta of 1.24. The stock has a fifty day moving average price of $576.22 and a 200 day moving average price of $589.48. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $732.17.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The firm's revenue for the quarter was up 31.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.15 earnings per share. On average, equities analysts anticipate that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Brittany Bagley sold 3,400 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the completion of the transaction, the chief financial officer now owns 131,833 shares in the company, valued at approximately $92,283,100. This represents a 2.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeri Williams sold 307 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the transaction, the director now owns 1,627 shares of the company's stock, valued at $899,275.44. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,764 shares of company stock worth $14,856,635. 4.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their price target on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday. Needham & Company LLC boosted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Northcoast Research cut Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Finally, Craig Hallum cut Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $652.73.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.